Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% ...

Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% ...

No significant difference was seen regarding progression-free survival between the tivozanib-nivolumab and tivozanib ...

Adding the drug nivolumab to AVD therapy halves the rate of cancer progression or death for blood cancer patients, compared ...

The following is a summary of “Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year ...

A decade-long study finds that nearly half of advanced melanoma patients survive cancer-free for 10 years with combined ...

Matthew R. Zibelman, MD, discusses differing opinions in muscle-invasive bladder cancer treatment he heard when moderating a ...

Recent clinical research from BGI Genomics and Zhongshan Hospital, Fudan University, highlights the effectiveness of ...

Rana R. McKay, MD, discusses the significance of clinical trial data for immunotherapy in muscle-invasive bladder cancer (MIBC) treatment she presented at a Case-Based Roundtable event.

This Industry Satellite Symposium was presented at the European Society for Medical Oncology (ESMO) Congress 2024, held in ...

Dr Meredith Edwards, Country Medical Director, Bristol Myers Squibb New Zealand, said, “The funding of OPDIVO as a treatment option for previously treated advanced clear cell renal cell carcinoma ...

Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% of patients with stage 3 ...